The Efficacy of Ustekinumab in the Remission Induction and Maintenance of Refractory Crohn's Disease

Kyeong Ok Kim; Byung Ik Jang

doi:10.4166/kjg.2013.61.1.58

Journal List > Korean J Gastroenterol > v.61(1) > 1007112

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim and Jang: The Efficacy of Ustekinumab in the Remission Induction and Maintenance of Refractory Crohn's Disease

Research Update

Korean J Gastroenterol 2013;61(1):58-60.

Published online: 4 October 2013

DOI: https://doi.org/10.4166/kjg.2013.61.1.58

The Efficacy of Ustekinumab in the Remission Induction and Maintenance of Refractory Crohn's Disease

Kyeong Ok Kim, Byung Ik Jang

Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea

Correspondence to: Byung Ik Jang, Department of Internal Medicine, Yeungnam University College of Medicine, 170 Hyunchung-ro, Nam-gu, Daegu 705-717, Korea. Tel: +82-53-620-3831, Fax: +82-53-654-8386, E-mail: jbi@med.yu.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

References

1. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132:52–65.

2. Sandborn WJ, Feagan BG, Stoinov S, et al. PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357:228–238.

3. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357:239–250.

4. Yamazaki K, Onouchi Y, Takazoe M, Kubo M, Nakamura Y, Hata A. Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn's disease in Japanese patients. J Hum Genet. 2007; 52:575–583.

5. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997; 112:1169–1178.

6. Parronchi P, Romagnani P, Annunziato F, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol. 1997; 150:823–832.

7. Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011; 3:535–545.

8. Becker C, Dornhoff H, Neufert C, et al. Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. J Immunol. 2006; 177:2760–2764.

9. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-IL-12 Crohn's Disease Study Group. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004; 351:2069–2079.

10. Neurath MF, Fuss I, Kelsall BL, Stüber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995; 182:1281–1290.

11. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cellmediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006; 116:1310–1316.

12. Sandborn WJ, Feagan BG, Fedorak RN, et al. Ustekinumab Crohn's Disease Study Group. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008; 135:1130–1141.

13. Leonardi CL, Kimball AB, Papp KA, et al. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008; 371:1665–1674.

14. Papp KA, Langley RG, Lebwohl M, et al. PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis:52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008; 371:1675–1684.

TOOLS

Similar articles